Synonym
R-Azasetron besylate; (R)-Azasetron besylate; UXP39EQ477; UNII-UXP39EQ477; 2025360-91-0
IUPAC/Chemical Name
(R)-6-chloro-4-methyl-3-oxo-N-(quinuclidin-3-yl)-3,4-dihydro-2H-benzo[b][1,4]oxazine-8-carboxamide benzenesulfonate
InChi Key
GFVBDLIBPSGFDL-ZOWNYOTGSA-N
InChi Code
InChI=1S/C17H20ClN3O3.C6H6O3S/c1-20-14-7-11(18)6-12(16(14)24-9-15(20)22)17(23)19-13-8-21-4-2-10(13)3-5-21;7-10(8,9)6-4-2-1-3-5-6/h6-7,10,13H,2-5,8-9H2,1H3,(H,19,23);1-5H,(H,7,8,9)/t13-;/m0./s1
SMILES Code
OS(=O)(=O)C1=CC=CC=C1.CN2C(=O)COC3=C(C=C(Cl)C=C23)C(=O)N[C@H]4CN5CCC4CC5
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
507.99
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Fang BX, Chen FC, Zhu D, Guo J, Wang LH. Stability of azasetron-dexamethasone mixture for chemotherapy-induced nausea and vomiting administration. Oncotarget. 2017 Oct 31;8(63):106249-106257. doi: 10.18632/oncotarget.22174. eCollection 2017 Dec 5. PubMed PMID: 29290945; PubMed Central PMCID: PMC5739730.
2: Petremann M, Tran Van Ba C, Broussy A, Romanet C, Dyhrfjeld-Johnsen J. Oral Administration of Clinical Stage Drug Candidate SENS-401 Effectively Reduces Cisplatin-induced Hearing Loss in Rats. Otol Neurotol. 2017 Oct;38(9):1355-1361. doi: 10.1097/MAO.0000000000001546. PubMed PMID: 28796092.
3: Kaito D, Iihara H, Funaguchi N, Endo J, Ito F, Yanase K, Toyoshi S, Sasaki Y, Hirose C, Arai N, Kitahora M, Ohno Y, Itoh Y, Minatoguchi S. Efficacy of Single-dose First-generation 5-HT(3) Receptor Antagonist and Dexamethasone for Preventing Nausea and Vomiting Induced by Low-dose Carboplatin-based Chemotherapy. Anticancer Res. 2017 Apr;37(4):1965-1970. PubMed PMID: 28373467.
4: Koshiyama M, Matsumura N, Imai S, Yamanoi K, Abiko K, Yoshioka Y, Yamaguchi K, Hamanishi J, Baba T, Konishi I. Combination of Aprepitant, Azasetron, and Dexamethasone as Antiemetic Prophylaxis in Women with Gynecologic Cancers Receiving Paclitaxel/Carboplatin Therapy. Med Sci Monit. 2017 Feb 15;23:826-833. PubMed PMID: 28198358; PubMed Central PMCID: PMC5322867.
5: Chen FC, Wang LH, Guo J, Shi XY, Fang BX. Simultaneous Determination of Dexamethasone, Ondansetron, Granisetron, Tropisetron, and Azasetron in Infusion Samples by HPLC with DAD Detection. J Anal Methods Chem. 2017;2017:6749087. doi: 10.1155/2017/6749087. Epub 2017 Jan 11. PubMed PMID: 28168082; PubMed Central PMCID: PMC5266853.
